Bacteriocins are proteinaceous substances that are ribosomally synthesised by bacteria exhibiting antagonistic activity usually against organisms that are closely related to the producer strain. Bacteriocins were originally characterised in *Escherichia coli* and their production has been demonstrated in a large variety of both Gram-positive and Gram-negative bacterial strains ([@B12], [@B23], [@B09]).

Several enterobacteria, mainly *E. coli,* express antagonistic activity attributed to the production of two groups of bacteriocins that are differentiated by their molecular mass and other properties. According to [@B09]), colicins are high-molecular-mass proteins ranging from 40-80 kDa and their release is generally lethal for the producing strain. There are two groups of colicins. Group A colicins translocate across the outer membrane via the Tol system and group B colicins utilise the Ton-dependent system ([@B18], [@B07], [@B25]).

By contrast, microcins are smaller peptides at 10 kDa or less and their synthesis is non-lethal for the producing strain and non-SOS-inducible ([@B04], [@B18], [@B21], [@B16]). According to a recent proposal, two major classes of microcins are classified. Class I corresponds to small peptides, less than 5 kDa, that are subjected to post-translational modifications. Class II includes larger microcins and is further divided into subclass IIa, which contains disulphide bonds, but do not undergo post-translational modification and subclass IIb, which gathers together those linear microcins that may carry a C-terminal post-translational modification ([@B13]).

The best-known colicins are produced by *E. coli*. More than 30 colicin types have been described and all but one are plasmid-encoded ([@B28], [@B09], [@B14]). *Shigella* strains produce several colicins, including the well-characterised Js and U colicins originally expressed by *Shigella sonnei* and *Shigella boydii,* respectively ([@B27], [@B17], [@B26]).

The synthesis of microcins is a more restricted phenomenon described almost exclusively for *E. coli* isolates. Fourteen microcins have been reported, of which seven are well studied. The production of microcins by *Shigella* strains has not been described ([@B21], [@B13]).

Several human health, livestock, food and environmental applications for bacteriocins have been suggested, including the control of bacterial diarrhoeal disease ([@B20], [@B28], [@B02]). Following the detection of bacteriocin expression, biochemical and physiological characterisation of the substance should be considered as a critical step that must precede any proposal for practical application. In this paper, we report the purification and partial characterisation of a new bacteriocin produced by an *S. sonnei* isolate.

SUBJECTS, MATERIALS AND METHODS
===============================

*Bacterial strains and media* - *S. sonnei* strains, named SS9 and SS12, were isolated from children with acute diarrhoea who presented for treatment at Children\'s Hospital João Paulo II/Hospital Foundation of the State of Minas Gerais, Belo Horizonte, Brazil. The isolates were selected as producer and indicator strains based on data obtained from a previous screening of antagonistic activity in several *S. sonnei* isolates ([@B29]).

The bacterial strains have been stored at -80ºC in Brucella Broth (Difco, Sparks, USA) with 10% glycerol (v/v). Before each experiment, the strains were subcultured three times onto tryptic soy agar (TSA) (Difco). Antagonistic tests were performed by employing the following culture media at pH 7.0, based on previously reported results ([@B29]): TSA, tryptic soy broth (TSB) (Difco) and TSB added with 0.7% Bacto agar (TSA-S) (Difco).

*Evaluation of the homogeneity of the antagonistic activity expression* - A 24-h broth culture of *S. sonnei* SS9 was serially diluted 10-fold (10^-1^-10^-8)^ in sterile 0.85% saline and plated onto TSA with a Drigalski loop. After incubation for 24 h at 37ºC, the number of isolated colonies was estimated and culture plates presenting 30-300 colonies were selected for determining the percentage of positive clones. Antagonism expression by each colony was identified using the double-layer method (Booth et al. 1977). The assay was performed in duplicate.

*Protein extraction* - *S. sonnei* SS9 was cultivated in 1200 mL TSB at 37ºC under aerobic conditions. After incubation for 12 h, the culture was centrifuged at 5,000 *g* at 4ºC for 30 min. To obtain the extracellular fractions S-50 and S-75, supernatant proteins were precipitated with 50% and 75% ammonium sulphate under constant slow stirring at 4ºC ([@B15]). The precipitate was collected by centrifugation at the same conditions, suspended in 0.01 M Tris-HCl pH 7.2 and dialysed (MEMBRA-CELL MC-18; Viskase, Darien, USA) against the same buffer at 4ºC overnight. The intracellular fractions C-30, C-75 and C-100 were obtained by sonicating the cells suspended in the same buffer for 12 cycles of 1 min at 50 W. Cellular disruption was checked by microscopy and the debris was removed by centrifugation at 25,410 *g* at 4ºC for 30 min. Next, the supernatant proteins were precipitated with 30%, 75% and 100% ammonium sulphate and processed as described for the extracellular fractions.

*Antagonistic activity assays, titration of crude bacteriocin and determination of the protein concentration* - Antagonistic activity assays were performed by the overlay method (Booth et al. 1977). Ten-microlitres aliquots of a 24-h culture of the indicator strain (*S. sonnei* SS9) were transferred to 3.5 mL of TSA-S and the inoculums were poured over TSA plates. Ten microlitres of each intracellular and extracellular fraction were dropped onto the surface of the medium. Evidence of activity was provided by the presence of growth inhibition zones of the indicator strain after incubation for 24 h at 37ºC under aerobic conditions. Active fractions were aliquoted and maintained at -80ºC.

Titration of antagonistic activity was performed as previously described ([@B32]). Aliquots of partially purified, active fractions were filtered and serially diluted two-fold in 0.01 M Tris-HCl pH 7.2 on microtitration plates (Micrower Plate 96F; Greiner Bioone, Frickenhausen, Germany). Antagonistic activity assays were performed as described. The titre, expressed as arbitrary units of bacteriocin per millilitre (AU/mL), was defined as the reciprocal of the highest dilution that inhibited the indicator strain.

The protein concentration was determined according to the method of Bradford (1976), using bovine serum albumin (Sigma, St Louis, USA) as a standard.

*Evaluation of antagonism expression along the growth curve* - After determining the growth curve of *S. sonnei* SS9, antagonism expression along the curve was evaluated. Ten-microlitres aliquots of broth culture of the producer strain were taken at some points of the growth curve (lag, exponential and stationary phases) and used for testing antagonistic activity. The titration of inhibitory activity was performed as described.

*Stability of the antagonistic substance* - The effect of pH, temperature and proteolytic enzymes on C-75 was evaluated by determining the preservation of antagonistic activity after each treatment, as described below.

*pH* - Values ranging from 1.0-11.0 were tested using KCl-HCl (pH 1.0, 2.0 and 3.0), acetate (pH 4.0 and 5.0), citrate (pH 6.0) and Tris-HCl (pH 7.0, 8.0, 9.0, 10.0 and 11.0) buffers. C-75 (AU = 1,600/mL) was diluted two-fold in each filter-sterilised (Millex-GV 0.22 µm PVDF; Millipore, County Cork, Ireland) buffer and the mixtures were incubated in a water bath at 37ºC for intervals of 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h and 24 h and 2, 3, 4, 7, 10, 15, 20, 25 and 30 days. Next, the mixtures were diluted two-fold (up to 1:8) in Milli-Q^(r)^ water (Millipore, Molsheim, France) and 10 µL of each mixture was placed onto the indicator culture, as described. C-75, diluted C-75 (1:2-1:8 in Milli-Q^(r)^ water) and buffers without C-75 were employed as controls.

*Temperature* - C-75 (AU = 800/mL) was treated at -80ºC, 5ºC, 25ºC, 37ºC, 50ºC, 70ºC and 100ºC for 20 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 14 h, 17 h and 24 h, 2, 3, 4, 7, 10, 12, 15, 20 and 30 days and 2, 3, 4, 6, 12, 18 and 24 months. After treatment, the temperature was set at 4ºC and each aliquot was diluted 1:2, 1:4 and 1:8 in Milli-Q^(r)^ water and tested for antagonistic activity as previously described. Untreated crude and diluted C-75 aliquots were employed as controls.

*Enzymes* - α-chymotrypsin, pepsin and trypsin (Sigma) diluted (1.0 mg/mL) in Tris-HCl (0.02 M, pH 8.0), papain (Sigma) diluted (1.0 mg/mL) in phosphate buffer (0.05 M, pH 7.0) and proteinase K (Sigma) diluted (1.0 mg/mL) in Tris-HCl (0.02 M, pH 7.2) were employed. The enzyme solutions were sterilised by filtration through a 0.22-µm membrane (Millex-GV). C-75 (AU = 3,200/mL, 1.0 mg/mL) was diluted 10-fold in each enzyme solution and the mixtures were incubated at 37ºC for 1 h and 4 h. C-75, C-75 diluted in each buffer, each buffer alone and the enzyme solutions were used as controls.

*Bacteriocin purification* - C-75 was submitted to ion-exchange chromatography on a fast performance liquid chromatography (FPLC) system using a Mono-Q^TM^ 5/50 GL column (GE Healthcare, Uppsala, Sweden) previously equilibrated with 0.02 M Tris-HCl (pH 8.0) and eluted with the same buffer using a gradient of 0-1.0 M NaCl in Tris-HCl (pH 8.0). Aliquots of 1.5 mL were collected and tested for antagonistic activity. Active fractions were pooled, concentrated by lyophilisation and submitted to the next purification step. Gel filtration chromatography was performed on a FPLC system using a Superose 12 HR 10/30 column (GE Healthcare) equilibrated with 0.02 M Tris-HCl (pH 8.0) added with 0.2 M NaCl and the samples were eluted with the same buffer. Active aliquots were individually submitted to reverse-phase chromatography on a high performance liquid chromatography (HPLC) system using a LiChroCart^(r)^ C18 column (250 x 4.0 mm) (Merck, Darmstadt, Germany). The mobile phases were 0.1% trifluoroacetic acid (TFA) and 80% aqueous acetonitrile solution containing 0.1% TFA. Aliquots were tested for antagonistic activity and the active fraction was lyophilised, suspended in Milli-Q^(r)^ water and submitted to mass spectrometry.

*Mass spectrometry* - The molecular mass of purified bacteriocin was determined via mass spectrometry analysis. The sample was dissolved in saturated sinapinic acid (5.0 mg of aqueous solution of 3% TFA: acetonitrile:water, 1:4:5, v/v) at a ratio of 1:3 (v/v) sample:matrix, transferred in triplicate (0.5 µL/well) for acquisition-board data MALDI (MTP AnchorChips 384 x 600; Bruker Daltonics, Billerica, USA) and maintained at room temperature. The molecular mass was determined with Autoflex^TM^ III MALDI-TOF/TOF (Bruker Daltonics) operating in the positive linear mode. A linear calibration was performed using Protein Calibration Standard II (Bruker Daltonics).

*Determination of the N-terminal amino acid sequence and sequence comparisons* - The protein sequence was determined by Edman degradation using a Shimadzu PPSQ-21A automated protein sequencer (Shimadzu, Kioto, Japan). For the homology analysis, the amino acid sequences were compared with other protein sequences, using the BLAST network service.

RESULTS
=======

*Population homogeneity and evaluation of antagonistic activity along the growth curve* - All *S. sonnei* SS9 isolates obtained from a single colony expressed antagonistic activity, indicating that the population is homogeneous.

Inhibitory activity was detected during the lag, exponential and stationary phases ([Fig. 1](#f01){ref-type="fig"}). The highest titre of activity was observed in the early stationary phase of bacterial growth (12,800 AU/mL).

Fig. 1:expression of antagonistic activity along the growth curve of Shigella sonnei SS9. AU: arbitrary unit.

*Antagonistic activity assays, titration of crude bacteriocin and determination of the protein concentration* - Intracellular fractions C-30, C-75 and C-100 and extracellular fraction S-50 exhibited antagonistic activity. C-75 was selected for partial characterisation assays on the basis of the largest amount of extract obtained and the highest titre of antagonistic activity ([Table I](#t01){ref-type="table"}).

TABLE ITitration and determination of protein concentration of active intracellular (C) and extracellular (S) fractions obtained after precipitation with 30%, 50%, 75% and 100% ammonium sulphateProtein fractionBacteriocin activity (AU/mL)Protein concentration (mg/mL)C-30102, 4001.12C-75\> 838, 860, 8002.79C-1004000.23S-508004.00[^1]

*Stability of the antagonistic substance* - The results describing the stability of C-75 are presented in [Table II](#t02){ref-type="table"}. C-75 maintained its activity for at least 24 h at pH values ranging from 1.0-11.0. At pH 5.0, 6.0 and 7.0, the inhibitory activity of the fraction was maintained for longer periods of time.

TABLE IIProperties of the intracellular fraction obtained after precipitation with 75% ammonium sulphate (C-75)TreatmentPeriod of timepH (37ºC)1.0, 2.0, 9.0, 10.0, 11.024 h3.03 days4.0, 8.04 days5.0, 6.025 days7.020 daysTemperatures (ºC) 100, 7020 min5017 days37, 2520 days5180 days-80\> 24 months

C-75 preserved its activity after incubation at temperatures ranging from -80-50ºC for at least 17 h. The aliquot of the extract that is preserved at -80ºC is still active after more than 24 months.

The extract was completely inactivated by 1-h exposure to proteinase K, papain, pepsin, trypsin and α-chymotrypsin.

*Bacteriocin purification* - In total, 37 fractions were obtained from ion-exchange chromatography. Among them, 17 exhibited antagonistic activity. Fractions 10-12 were combined and the originated pool was selected for the subsequent steps of the study because of its highest titre of antagonistic activity and the profile generated by gel filtration chromatography ([Fig. 2A](#f02){ref-type="fig"}). Among the 27 fractions collected from gel filtration chromatography, eight (fractions 5-12) expressed activity and each was individually submitted to reverse-phase chromatography. Only one of the fractions derived from reverse-phase chromatography displayed activity (36.4-min retention time) ([Fig. 2B](#f02){ref-type="fig"}). At the end of the sequential purification steps, 22.2 µg of purified protein (800 AU/mL) was obtained. Although a high specific activity was recovered, an extremely low percent yield was observed ([Table III](#t02){ref-type="table"}).

Fig. 2:purification steps of Shigella sonnei SS9 bacteriocin. A: gel filtration (fast performance liquid chromatogram; active fractions: 5-12); B: C18 reverse phase \[high performance liquid chromatogram; mobile phase A: 0.1% trifluoroacetic acid (TFA); mobile phase B: 80% aqueous acetonitrile solution containing 0.1% TFA; linear gradient 0-100% of B solution in 30 min flow rate 1 mL/min, temperature 35ºC; active fraction: 36.4 min retention time\]; C: mass spectrum of purified bacteriocin (the estimated average molecular mass of the protein was 18.56 kDa). AU: arbitrary unit.

TABLE IIIBacteriocin activity, protein concentration, specific activity, fold purification and percent yield during purification stepsProtein fraction/obtained fromBacteriocin activity (AU/mL)Total protein concentration (mg)Volume (mL)Specific activity (AU/mL x mg ^-1^ )Fold purificationYield (%)C-75/ammonium sulphate precipitation16,384140.416.6116.71.0100Fractions 10-12/ion exchange chromatography1,6002.736.0592.65.121.2Fraction 11/gel filtration chromatography1,6000.277.55,925.950.84.4Active fraction/reverse phase chromatography8000.020.0540,000.0342.80.01[^2]

*Mass spectrometry* - Analysis by spectrometry revealed that the estimated average molecular mass of the bacteriocin was 18.56 kDa. [Fig. 2C](#f02){ref-type="fig"} depicts the +1, +2 and +3 charged species of the purified protein.

*Determination of the N-terminal amino acid sequence* - N-terminal amino acid sequencing yielded the following sequence: Ser - Tre - Ala - Lys - Leu - Val - Lys - Ser - Lys - Ala - Tre - Asn - Leu - Leu - Tyr - Tre - Arg - Asn - Asp - Val. The sequence displayed identity with 20 different proteins (100% of identity with 8 proteins, 90% identity with 6 proteins and 80% and 75% identity with 3 proteins each) that seem to be associated with DNA protection during starvation, particularly iron binding and storage. None of the proteins has been described as an antagonistic substance. Among the eight proteins that exhibited 100% identity, four were described for *E. coli* and one for *Klebsiella pneumoniae*, *Proteus vulgaris*, *Shigella flexneri* and *Enterobacter cloacae*.

DISCUSSION
==========

The production of bacteriocins in special colicins has been reported not only for enterobacteria, mainly *E. coli,* but also for other genera such as *Shigella* ([@B23], [@B09]). However, most studies on *S. sonnei* colicins refer to bacteriocinotyping based on the production of and sensitivity to these substances, which is useful for epidemiological purposes and has been employed to differentiate isolates associated with shigellosis outbreaks ([@B01], [@B10]). To the best of our knowledge, there are few studies on the purification and characterisation of *Shigella* bacteriocins ([@B27], [@B26]).

Among the active extracts obtained following ammonium sulphate precipitation, C-75 was selected for partial characterisation assays on the basis of the largest amount of the fraction and the highest titre of antagonistic activity. Although we selected an intracellular fraction, we believe that the antagonistic substance found in C-75 may be exported under several circumstances, such as stress. Indeed, the detection of antagonistic activity by the overlay method employing the producer bacterial strain demonstrates the secretion of antagonistic substance(s) by the organism.

The proteinaceous nature of C-75 was confirmed by its inactivation after treatment with proteolytic enzymes. The thermolability of the extract is also consistent with its chemical constitution and corroborates data reported by other authors who have demonstrated that colicins produced by *Shigella* are generally heat-labile ([@B22], [@B09]). Similar results were obtained for the extracellular fraction precipitated at a 75% salt concentration, as previously described by our group ([@B29]).

In general, C-75 showed to be stable, keeping active after exposure to different pHs and temperatures in some cases for long periods. It should be highlighted that the aliquot maintained at -80ºC is still active after more than two years. Besides making studies easier stability is such a desirable characteristic for a substance that has the potential for practical applications.

C-75 bound to the Mono-Q column indicated that the protein is anionic. Although N-terminal sequencing of the substance revealed that 13 of 20 amino acids were hydrophilic, the reverse-phase chromatography results suggest that overall the protein is hydrophobic.

A low output of purified protein and a low titre of antibacterial activity were observed after completion of the sequential chromatography steps. The yield from the purification procedure clearly demonstrates that the purification procedure should be optimised to obtain significant amounts of active, purified protein.

Bacteriocins are still loosely defined antibacterial substances and the definition of specific bacteriocin categories, such as colicins and microcins, is controversial. According to several authors, microcins are sized as up to 10 kDa and although there is not a consensual determination of the colicin molecular-mass range, the smallest described substances are 40 kDa, 25 kDa or at least 20 kDa ([@B21], [@B16], [@B09]). The analysis of mass spectrometry data demonstrated that the purified protein obtained in the present study has an estimated molecular mass of 18.56 kDa, suggesting that the protein is a new bacteriocin that does not match any previously described bacteriocin.

The N-terminal amino acid sequence displayed identity with 20 different bacterial proteins and none of them is associated with bacterial antagonism. Their predicted function is related to DNA protection during starvation, particularly iron-binding and storage. It is interesting to highlight that unfavourable conditions, such as nutrient depletion, also stimulate bacteriocin expression ([@B09], [@B13]).

One of the eight proteins that presented 100% N-terminal sequence identity (20 amino acids) with the bacteriocin described in this study is PexB, an 18-kDa, membrane-associated *E. coli* polypeptide that is induced early during starvation conditions ([@B03], [@B19], [@B08]). The structure, function and regulation of the DNA-binding protein Dps and its role in acid and oxidative-stress resistance have been determined. Considering the sequence and mass similarity and that *S. sonnei* and *E. coli* exhibit a high degree of genetic relatedness, PexB and Dps might be the same protein. However, bacteriocin activity has not been reported for PexB.

Although the antagonistic substance is not fully characterised, our results raise two possibilities: that the bacteriocin is a newly described protein or that it represents an already described protein with a newly detected function. The substance is possibly a colicin that does not fit the established molecular-mass ranges defined for colicins (at least 20 kDa) and microcins (no more than 10 kDa) ([@B21], [@B16], [@B09]).

Colicins are an alternative mean to prevent infections associated with *E. coli* and related microorganisms. Antagonistic activity against diarrhoeagenic and uropathogenic *E. coli,* including the prevention of diarrhoea in livestock, has already been reported ([@B20], [@B24], [@B30], [@B31], [@B11]). Because *S. sonnei* SS9 exhibited antagonistic activity against other diarrhoeagenic bacteria such as *S. flexneri* and enteroinvasive *E. coli* ([@B29]), this bacteriocin may contribute to bacterium virulence. Moreover, the protein has a potential clinical applicability as an alternative option for controlling and preventing diarrhoeal disease. However, before this bacteriocin can be practically applied, further studies of its structural and functional properties are mandatory.
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[^1]: Shigella sonnei SS9 grown in tryptic soy broth for 12 h at 37ºC. AU: arbitrary unit.

[^2]: AU: arbitrary unit.
